Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Living up to the reputation of being a Gen Z style icon, the ‘Bridgerton’ actress created a golden hour moment at the ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

Pittman rejected a separate challenge in May brought by the same groups over the FDA's removal of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro from the shortage list.

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the drugs, was ...

If you have other questions about Wegovy and interactions with food, such as foods to avoid when receiving Wegovy, talk with your doctor. They may have more specific instructions for the diet you ...

The federal government allowed compounding pharmacies to sell copies of GLP-1 drugs while the medications were in short supply. But the Food and Drug Administration said the shortages of Wegovy ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

New research shows that semaglutide, the compound in the weight-loss drug Wegovy, could treat an increasingly common liver disease. The study, published Wednesday in the New England Journal of ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...